Interethnic differences of CYP2C9 alleles in healthy Hungarian and Roma population samples: Relationship to worldwide allelic frequencies

被引:29
作者
Sipeky, Csilla [1 ]
Lakner, Lilla [2 ]
Szabo, Melinda [3 ]
Takacs, Istvan [4 ]
Tamasi, Viola [5 ]
Polgar, Noemi [1 ]
Falus, Andras [5 ]
Melegh, Bela [1 ]
机构
[1] Univ Pecs, Dept Med Genet, H-7624 Pecs, Hungary
[2] Markusovszky Hosp, Dept Gastroenterol & Med, H-9700 Szombathely, Hungary
[3] Robert Koch Hosp, H-3780 Edeleny, Hungary
[4] Med Ctr Miskolc, Dept Internal Med & Haematol, H-3529 Miskolc, Hungary
[5] Semmelweis Univ, Dept Genet Cell & Immunobiol, H-1445 Budapest, Hungary
基金
美国国家科学基金会;
关键词
CYP2C9; Anticoagulants; Warfarin; Interethnic differences; Hungarian; Roma; CYTOCHROME P4502C9; GENETIC POLYMORPHISMS; GENOTYPE FREQUENCIES; MUTANT ALLELES; Y-CHROMOSOME; WARFARIN; PHARMACOGENETICS; VARIANTS; JAPANESE; METABOLISM;
D O I
10.1016/j.bcmd.2009.05.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
CYP2C9 gene polymorphisms are widely studied in several ethnic groups, however they are less known in the Roma population. The aim of this work was to study the ethnic differences of the CYP2C9 allele distribution in a healthy Roma population in order to compare them with a healthy Hungarian population. A total of 535 Hungarian and 465 Roma volunteers were genotyped for the CYP2C9*2 (Arg144Cys) and CYP2C9*3 (Ile359Leu) allelic variants by PCR-RFLP assay. The frequencies of the CYP2C9*1, *2 and *3 alleles in the Hungarian population were 0.787, 0.125, and 0.088 and in Roma 0.727, 0.118, and 0.155, respectively. We found a significant difference in CYP2C9*3 prevalence between the Hungarian and Roma populations, which have therapeutic consequences (p<0.005). The distribution of *1/*1, *1/*2, *1/*3, *2/*2, *2/*3, and *3/*3 genotypes in Hungarians were 0.620, 0.195, 0.139, 0.021, 0.015, and 0.011, while in Roma were 0.533, 0.168, 0.219, 0.011, 0.047, and 0.022, respectively. A significant difference was found between the Hungarian and Roma populations regarding the *1/*1, *1/*3 and the *2/*3 (p<0.005) genotypes. This is the first study to investigate the polymorphisms of CYP2C9 gene in the two largest populations in Hungary, healthy Hungarians and Roma. The prevalence of variant CYP2C9 alleles in the Hungarian population is similar to that observed in other European populations. In contrast, the Roma population differs from Hungarians, from most of other Caucasian groups, and from Indians in the incidence of CYP2C9 common variants. The difference in allele distribution patterns between the two populations studied has therapeutic implications as it influences the optimization of therapies. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:239 / 242
页数:4
相关论文
共 59 条
  • [1] Allele and genotype frequency of CYP2C9 in Tamilnadu population
    Adithan, C
    Gerard, N
    Vasu, S
    Balakrishnan, R
    Shashindran, CH
    Krishnamoorthy, R
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 59 (8-9) : 707 - 709
  • [2] Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
    Aithal, GP
    Day, CP
    Kesteven, PJL
    Daly, AK
    [J]. LANCET, 1999, 353 (9154) : 717 - 719
  • [3] Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations
    Allabi, AC
    Gala, JL
    Desager, JP
    Heusterspreute, M
    Horsmans, Y
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 56 (06) : 653 - 657
  • [4] Aynacioglu AS, 1999, BRIT J CLIN PHARMACO, V48, P409
  • [5] Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice
    Becquemont, Laurent
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 64 (10) : 953 - 960
  • [6] GEOGRAPHICAL INTERRACIAL DIFFERENCES IN POLYMORPHIC DRUG OXIDATION - CURRENT STATE OF KNOWLEDGE OF CYTOCHROMES P450 (CYP) 2D6 AND 2C19
    BERTILSSON, L
    [J]. CLINICAL PHARMACOKINETICS, 1995, 29 (03) : 192 - 209
  • [7] Bozina N, 2003, CROAT MED J, V44, P425
  • [8] Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population:: an investigative and comparative study
    Bravo-Villalta, HV
    Yamamoto, K
    Nakamura, K
    Bayá, A
    Okada, Y
    Horiuchi, R
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 61 (03) : 179 - 184
  • [9] Pharmacogenetics of oral anticoagulants
    Daly, AK
    King, BP
    [J]. PHARMACOGENETICS, 2003, 13 (05): : 247 - 252
  • [10] METABOLIC POLYMORPHISMS
    DALY, AK
    CHOLERTON, S
    GREGORY, W
    IDLE, JR
    [J]. PHARMACOLOGY & THERAPEUTICS, 1993, 57 (2-3) : 129 - 160